Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1994-12-05
1999-10-12
Kight, John
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
424 88, 424 145, 4241391, 4241561, 4241831, 5303917, 5303919, 5303872, 530807, 530828, 435 701, 435 702, 4351822, 4352402, A61K 5100
Patent
active
059651326
ABSTRACT:
The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.
REFERENCES:
patent: 4456550 (1984-06-01), Dvorak et al.
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4536387 (1985-08-01), Sakamoto et al.
patent: 5021236 (1991-06-01), Gries et al.
patent: 5036003 (1991-07-01), Olander et al.
patent: 5081034 (1992-01-01), Bevilacqua et al.
patent: 5342757 (1994-08-01), Garin-Chesa et al.
patent: 5360896 (1994-11-01), Senoo et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5403713 (1995-04-01), Bevilacqua et al.
patent: 5571714 (1996-11-01), Dasch et al.
patent: 5612212 (1997-03-01), Gewirtz
patent: 5632991 (1997-06-01), Gimbrone, Jr.
patent: 5659013 (1997-08-01), Senger et al.
Osband and Ross, "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy," Immunotherapy, 11:193-195, 1990.
Chatterjee, et al., Idiotypic antibody immunotherapy of cancer Cancer Immunol. Immunotherapy, 38:75-82, 1994.
Plate, Karl H. et al., "Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo," Nature, 359:845-848, 1992.
Rettig, Wolfgang J. et al., "Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer," Proc. Natl. Acad. Sci. USA, 89:10832-10836, 1992.
Sarma, Vidya et al., "Cloning of a Novel Tumor Necrosis Factor-.alpha.-Inducible Primary Response Gene that is Differentially Expressed in Development and Capillary Tube-Like Formation in vitro," The Journal of Immunology, 148:3302-3312, 1992.
Senger, Donald R. et al., "Vascular permeability factor (VPF, VEGF) in tumor biology," Cancer and Metatasts Reviews, 12:303-324, 1993.
Shweiki, Dorit et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," Nature, 359:843-845, 1992.
Wang, J.M. et al., "A Monoclonal Antibody Detects Heterogeneity in Vascular Endothelium of Tumours and Normal Tissues," Int. J. Cancer, 54:363-370, 1993.
Westphal, Johan R. et al., "A New 180-kDa Dermal Endothelial Cell Activation Antigen: In Vitro and In Situ Characteristics," The Journal of Investigative Dermatology,100(1):27-34, 1993.
Yeo, Kiang-Teck et al., "Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Guinea Pig and Human Tumor and Inflammatory Effusions," Cancer Research, 53:2912-2918, 1993.
Aoyagi, "Distribution of Plasma Fibronectin in the Metastatic Lesion of Cancer: Experimental Study by Autoradiography," Thrombosis Research, 49:265-75, 1988.
Balza et al., "Production and Characterization of Monoclonal Antibodies Specific for Different Epitopes of Human Tenascin," FEBS 332(1,2):39-43, 1993.
Bjorndahl, et al., "Human T Cell Activation: Differential Response to Anti-CD28 As Compared to Anti-CD3 Monoclonal Antibodies," Eur. J. Immunol. 19:881-87, 1989.
Blanchard, et al., "Infiltration of Interleukin-2-Inducible Killer Cells in Ascitic Fluid and Pleural Effusions of Advanced Cancer Patients," Cancer Research, 48:6321-27, 1988.
Bohlen, et al., "Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies," Cancer Research, 53:4310-14, 1993.
Borsi, et al., "Expression of Different Tenascin Isoforms in Normal, Hyperplastic and Neoplastic Human Breast Tissues," Int. J. Cancer, 52:688-92, 1992.
Boyer, et al., "Differential Induction by Interferons of Major Histocompatibility Complex-Encoded and Non-Major Histocompatibility Complex-Encoded Antigens in Human Breast and Ovarian Carcinoma Cell Lines," Cancer Research, 49:2928-34, 1989.
Burton-Wurster, et al., "Expression of the Ed B Fibronectin Isoform in Adult Human Articular Cartilage," Biochemical and Biophysical Research Communication 165(2):782-87, 1989.
Collins, et al., "Immune Interferon Activates Multiple Class II Major Histocompatibility Complex Genes and the Associated Invariant Chain Gene in Human Endothelial Cells and Dermal Fibroblasts," Proc. Natl. Acad. Sci. USA, 81:4917-21, 1984.
Carnemolla et al., "A Tumor-associated Fibronectin Isoform Generated by Alternative Splicing of Messenger RNA Precursors," The Journal of Cell Biology, 108:1139-48, 1989.
Carnemolla et al., "The Inclusion of the Type III Repeat ED-B in the Fibronectin Molecule Generates Conformational Modifications that Unmask a Cryptic Sequence," The Journal of Biological Chemistry, 267(34):24589-92, 1992.
Carnemolla, et al., "Phage Antibodies with Pan-Species Recognition of the Oncofoetal Angiogenesis Marker Fibronectin ED-B Domain," Int. J. Cancer, 68:397-405, 1996.
Castellani, et al., "The Fibronectin Isoform Containing the ED-B Oncofoetal Domain: A Marker of Angiogenesis," Int. J. Cancer, 59:612-18, 1994.
Conforti, et al., "Human Endothelial Cells Express Integrin Receptors on the Luminal Aspect of Their Membrane," Blood 80(2):437-46, 1992.
Dillman, "Monoclonal Antibodies for Treating Cancer," Annals of Internal Medicine, 111(7): 592-600, 1989.
Farnoud, et al., "Fibronectin Isoforms Are Differentially Expressed in Normal and Adenomatous Human Anterior Pituitaries," Int. J. Cancer, 61:27-34, 1995.
Garin-Chesa, et al., "Cell Surface Glycoprotein of Reactive Stromal Fibroblasts As A Potential Antibody Target in Human Epithelial Cancers," Proc. Natl. Acad. Sci. USA, 87:7235-39, 1990.
Groenewegen, et al., "Lymphokine Dependence of In Vivo Expression of MHC Class II Antigens by Endothelium," Nature, 316:361-63, 1985.
Harris and Emery, "Therapeutic Antibodies -The Coming of the Age," Btech, 11:42-44, 1993.
June, et al., "T-Cell Proliferation Involving the CD28 Pathway Is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression," Molecular and Cellular Biology 7(12):4473-81, 1987.
Kaczmarek, et al., "Distribution of Oncofetal Fibronectin Isoforms in Normal Hyperplastic and Neoplastic Human Breast Tissues," Int. J. Cancer, 58:11-16, 1994.
Koulova et al., "The CD28 Ligand B7/BB1 Provides Costimulatory Signal for Alloactivation of CD4.sup.+ T Cells," J. Exp. Med. 173:759-62, 1991.
Kurosawa, et al., "Early Appearance and Activation of Natural Killer Cells in Tumor-Infiltrating Lymphoid Cells During Tumor Development," Eur. J. Immunol. 23:1029-33, 1993.
Lampugnani, et al., "The Role of Integrins in the Maintenance of Endothelial Monolayer Integrity," The Journal of Cell Biology, 112(3):479-90, 1991.
Linnala, et al., "Human Amnion Epithelial Cells Assemble Tenascins and Three Fibronectin Isoforms in the Extracellular Matrix," FEBS, 314(1,2):74-78, 1993.
Maeda, et al., "Production and Characterization of Tumor Infiltrating Lymphocyte Clones Derived from B16-F10 Murine Melanoma," The Journal of Investigative Dermatology 97(2):183-89, 1991.
Natali, et al., "Comparative Analysis of the Expression of the Extracellular Matrix Protein Tenascin in Normal Human Fetal, Adult and Tumor Tissues," Int. J. Cancer, 47:811-16, 1991.
Oyama, et al., "Coordinate Oncodevelopmental Modulation of Alternative Splicing of Fibronectin Pre-Messenger RNA at ED-A, ED-B and CS1 Regions in Human Liver Tumors," Cancer Research 53:2005-11, 1993.
Peters, et al., "Expression of the Alternatively Spliced EIIIB Segment of Fibronectin," Cell Adhesion and Communication, 3:67-89, 1995.
Pober et al., "Ia Expression by Vascular Endothelial Is Indcuible by Activated T Cells and by Human .gamma. Interferon," J. Exp. Med. 157: 1339-53, 1983.
Pohl, et al., "CD30-Antigen-Specific Targeting and Activation of T Cells via Murine Bispecific Monoclonal Antibodies Against CD3 and CD28: Potential Use for the Treatment of Hodgkin's Lymphoma," Int. J. Cancer, 54:820-27, 1993.
Renner, et al., "Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells," Science, 264:833-35, 1994.
Rettig, et al., "Cell-Sur
Burrows Francis J.
Thorpe Philip E.
Board of Regents , The University of Texas System
Hartley Michael G.
Kight John
LandOfFree
Methods and compositions for targeting the vasculature of solid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for targeting the vasculature of solid , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for targeting the vasculature of solid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-649422